Quidel Corp. (QDEL) PT Raised to $27 at Barclays; Reiterates Overweight

Barclays raised its price target on Quidel Corp. (NASDAQ: QDEL) to $27.00 (from $26.00) while maintaining a Overweight rating. QDEL reported 1Q revenues of $73.7 million, beating estimates of $62.4 million by 18%. The beat was driven by a more aggressive-than-expected flu season.

Analyst Jack Meehan believes that the company's innovation in point-of-care testing fits well into broader trends related to healthcare consumerism.

You May Also Be Interested In

• Everplay Group Plc (EVPL:LN) PT Raised to GBP5.45 at RBC Capital
• Barclays Starts Hill & Smith Holdings Plc. (HILS:LN) at Overweight
• Goldman Sachs Upgrades RENK Group AG (R3NK:GR) to Buy